High-risk percutaneous coronary intervention (high-risk PCI) can be complicated by hemodynamic instability. Prophylactic veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been used to provide hemodynamic support during such procedures, but routine prophylactic use carries risks and may be unnecessary in many patients. To address the balance between potential benefit and harms, the ECMO-READY investigators developed a strategy of pre-cannulated standby ECMO and designed a randomized trial to compare this approach with standard prophylactic ECMO.
The trial aims to generate prospective randomized evidence to inform the optimal use of VA-ECMO support during high-risk PCI.
ECMO-READY is a prospective, multicenter, open-label, randomized controlled trial conducted at eight sites in China. The protocol specifies random allocation of participants to one of two ECMO strategies in a 1:1 ratio. The trial is described as a pragmatic comparison of two peri-procedural ECMO approaches in patients scheduled for high-risk PCI.
A total of 176 patients scheduled to undergo high-risk PCI will be enrolled. Specific eligibility criteria and inclusion/exclusion details were reported in the protocol but are not reproduced in full in the source summary. Enrollment began in March 2025, with anticipated completion of enrollment by December 2026.
Participants will be randomized in a 1:1 ratio to either the pre-cannulated standby ECMO group or the prophylactic ECMO group. The trial is open-label; treating teams and investigators will be aware of allocation. The source does not provide further operational details of the randomization method in the abstract.
The two comparator strategies are:
Pre-cannulated standby ECMO: patients are pre-cannulated so that ECMO support can be initiated rapidly if clinically required during or after PCI. The intent is to have ECMO readily available without routine initiation for all patients.
Prophylactic ECMO: patients receive active ECMO support prophylactically before or during the high-risk PCI procedure.
The full procedural and management protocols for cannulation, initiation, criteria for ECMO initiation or weaning, and other management specifics are outlined in the full protocol; the abstract summarizes the strategies but does not detail procedural algorithms.
The primary outcome is the 30-day incidence of a composite of major adverse events. The composite includes: death, myocardial infarction, repeat revascularization, stroke, PCI failure, limb ischemia, major bleeding, vascular injury requiring intervention, and need for renal replacement therapy.
Secondary outcomes specified in the protocol include:
These outcomes aim to capture procedural safety, bleeding and inflammatory response, resource use, and the specific clinical events composing the primary endpoint.
The trial plans to enroll 176 patients randomized 1:1. Enrollment commenced in March 2025 and is anticipated to conclude in December 2026. Details of the sample size calculation (assumptions, effect size, power) were not included in the abstract summary.
The study received ethical approval from the Ethics committee/IRB of Beijing Anzhen Hospital, Capital Medical University (Approval ID: KS2024014). The trial is registered on ClinicalTrials.gov under identifier NCT06274411; the registration date reported was February 23, 2024.
The authors state that all necessary patient consent and institutional approvals were obtained. The protocol notes that all data produced in the study will be available upon reasonable request to the authors.
Funding sources declared in the protocol include the Noncommunicable Chronic Diseases-National Science and Technology Major Project (grants 2025ZD0547900 and 2025ZD0547904), the Beijing Nova Program (202604841397), and Beijing Anzhen Hospital high-level research funding (2025AZB6017 and 2025AZA3003).
The authors have declared no competing interests.
The ECMO-READY trial is intended to provide randomized evidence comparing a pre-cannulated standby ECMO strategy with prophylactic ECMO in patients undergoing high-risk PCI. By measuring a composite of major clinical events at 30 days and multiple secondary safety and resource-use endpoints, the study seeks to inform whether routine prophylactic ECMO confers net clinical benefit compared with having ECMO available on standby.
Because this protocol report is a preprint and has not undergone peer review, its findings and recommendations are not yet suitable to change clinical practice. The trial’s results, when available, will be important for clinicians and centers that perform high-risk PCI and consider peri-procedural mechanical circulatory support strategies.
The source document is the trial protocol abstract posted as a medRxiv preprint. Specific operational details—such as full eligibility criteria, randomization method, blinding (beyond open-label status), sample size calculation parameters, and detailed procedural algorithms—were not reported in the abstract section provided here. Interested readers should consult the full protocol or trial registry entry (NCT06274411) for complete methodological details.